bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.?The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent ?-thalassemia (TDT).
| Revenue (Most Recent Fiscal Year) | $83.81B |
| Net Income (Most Recent Fiscal Year) | $-240.71M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.43 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -287.14% |
| Net Margin (Trailing 12 Months) | -287.23% |
| Return on Equity (Trailing 12 Months) | -656.32% |
| Return on Assets (Trailing 12 Months) | -45.81% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.96 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.24 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-23.74 |
| Earnings per Share (Most Recent Fiscal Year) | $-24.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-45.54 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.79M |
| Free Float | 9.65M |
| Market Capitalization | $36.32M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 0.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 87.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |